Media Coverage

Study suggests ELIAS can boost survival time with canine cancer immunotherapy


Oct 26, 2018 - Animal Pharm
By Joseph Harvey

ELIAS Animal Health claims a new study suggests its experimental cancer immunotherapy "may improve survival times in dogs with cancer".

The clinical-stage firm has secured positive results from a canine osteosarcoma immunotherapy trial. The study evaluated its autologous prescription product ECI (ELIAS Cancer Immunotherapy) and highlighted a median survival time (MST) of 415 days in animals completing therapy.

This MST is in comparison to historical survival time of 134 days with surgery alone. ELIAS will include these results in its submission to the USDA during the fourth quarter of 2018.

"The trial included 15 dogs diagnosed with osteosarcoma, an aggressively metastatic primary bone malignancy with frequent chemotherapy failure," the firm explained. "The most common adverse events reported were mild and transient in nature, and primarily included inappetence, fever, gastrointestinal disturbances and lethargy."

Earlier this year, ELIAS discussed positive preliminary findings from this study.

The Olathe, Kansas-based business will begin a larger field safety and efficacy study in early 2019. While the company is pushing for further osteosarcoma studies and commercialization, it is also exploring the viability of its technology in other cancers such as lymphoma.

ECI is a combination of cancer vaccination pre-treatment and activated 'killer' T cell immunotherapy. ELIAS said it is the only product of its kind available in veterinary oncology. The cancer immunotherapy is being distributed to veterinarians as an experimental product – the product's efficacy and safety have not yet been established.

ELIAS is currently aiming to raise $5 million in financing to aid commercialization of ECI and to support additional clinical trials. In June, the company significantly expanded its leadership team to include Steve Sewell as chief operating officer, add Lee Herron to its scientific advisory board and introduce Julia Stephanus and Kip Wiggins to its board. 

Reprinted with permission of Animal Pharm News

Share

Search

Archive

Agenda

Registration

Application

Selection Committee

Judging Panel

Sponsors

Conference Materials

Business Partnering

Venue/ Accommodations

Media